|Systematic (IUPAC) name|
|(1S,2R,5R,7R,8R,9S,11R,13R,14R)-8-[(2S,3R,4S,6R)- 4-Dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13- hexamethyl-9-[(E)-3-quinolin-3-ylprop-2-enoxy] -3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone|
|Legal status||Phase III Clinical Trials in US|
|Bioavailability||Between 35.8 and 60 % in animal studies.|
|Half-life||1.6, 3.0, 4.5, 5.9 and 6 hours. Mouse, Monkey, Rat, Dog and Human respectively.|
|Excretion||7.0% urine 87.2% faeces|
|Mol. mass||765.931 g/mol|
|Melt. point||211–213 °C (412–415 °F)|
|(what is this?)|
Cethromycin (initially known as ABT-773) is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication. Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.
On October 1, 2008 Advanced Life Sciences submitted a New Drug Application (NDA) to Food and Drug Administration (FDA) for cethromycin to treat mild-to-moderate community acquired pneumonia.
On December 3, 2008 Advanced Life Sciences announced that this New Drug Application has been accepted for filing by the FDA.